GB-2064 is under clinical development by Galecto and currently in Phase II for Myelofibrosis. According to GlobalData, Phase II drugs for Myelofibrosis have a 43% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how GB-2064’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
GB-2064 overview
GB-2064 (PAT-1251) Is under development for the treatment of primary myelofibrosis and secondary myelofibrosis. The drug candidate is administered through oral route in the form of tablet. It acts by targeting LOXL2. It was also under development for the treatment of idiopathic pulmonary fibrosis, liver fibrosis and kidney fibrosis.
Galecto overview
Galecto is a drug development company. It focuses on the development of galectin modulators for the treatment of cancer, fibrosis and inflammation. The company develops activators and inhibitors of galectins. Its pipeline products include GB0139 to treat
For a complete picture of GB-2064’s drug-specific PTSR and LoA scores, buy the report here.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.
